Suleman Muhammad, Khan Safir Ullah, Jabeen Hina, Madkhali Osama A, Bakkari Mohammed Ali, Alsalhi Abdullah, Yassine Hadi M, Crovella Sergio
Laboratory of Animal Research Center (LARC), Qatar University, Doha, Qatar.
Center for Biotechnology and Microbiology, University of Swat, Swat, Pakistan.
Curr Gene Ther. 2025 Jul 11. doi: 10.2174/0115665232336511250626200218.
Enterovirus D68 (EV-D68) is a non-enveloped, positive-sense, singlestranded RNA virus known for causing severe respiratory illnesses and its association with acute flaccid myelitis (AFM) in children. Despite its increasing public health significance, no vaccines or antiviral drugs are currently available for EV-D68. This study aimed to design an immune-boosting multi-epitope subunit vaccine against EV-D68 using advanced immunoinformatic and machine learning approaches.
Capsid proteins VP1, VP2, and VP3 of EV-D68 were screened for immunogenic HTL, CTL, and B-cell epitopes to develop a non-allergenic, highly immunogenic multi-epitope vaccine. Predicted epitopes were subjected to 3D structural modeling and molecular dynamics simulations to validate folding and structural stability. Molecular docking and immune simulation techniques were employed to evaluate vaccine-TLR3 interactions and predict immune responses, respectively.
Molecular docking analysis revealed strong binding affinities between the vaccine constructs and the TLR3 receptor, with scores of -299 kcal/mol, -361 kcal/mol, -258 kcal/mol, and -312 kcal/mol for VP1, VP2, VP3, and combined vaccine-TLR3 complexes. Molecular dynamic simulation and dissociation constant analyses confirmed the strength of these interactions, with binding free energies ranging from -57.75 kcal/mol to -101.35 kcal/mol. Codon adaptation index (CAI) values of 0.96 and GC content of ~69% supported the high expression potential of the vaccine constructs. Immune simulations demonstrated robust immune responses characterized by elevated IgG, IgM, cytokines, and interleukins, along with effective antigen clearance.
The strong molecular interactions with TLR3 and simulated immune responses suggest that the designed vaccines can activate both innate and adaptive immunity. The high CAI and GC values support their expression feasibility in , enhancing prospects for production.
This study provides a strong foundation for the development of a safe and effective EV-D68 vaccine, showcasing the potential of computational vaccine design.
肠道病毒D68(EV-D68)是一种无包膜的正链单链RNA病毒,以引起严重呼吸道疾病以及与儿童急性弛缓性脊髓炎(AFM)的关联而闻名。尽管其对公共卫生的重要性日益增加,但目前尚无针对EV-D68的疫苗或抗病毒药物。本研究旨在使用先进的免疫信息学和机器学习方法设计一种针对EV-D68的增强免疫多表位亚单位疫苗。
对EV-D68的衣壳蛋白VP1、VP2和VP3进行免疫原性HTL、CTL和B细胞表位筛选,以开发一种无过敏原、高免疫原性的多表位疫苗。对预测的表位进行三维结构建模和分子动力学模拟,以验证折叠和结构稳定性。分别采用分子对接和免疫模拟技术评估疫苗与TLR3的相互作用并预测免疫反应。
分子对接分析显示,疫苗构建体与TLR3受体之间具有很强的结合亲和力,VP1、VP2、VP3和联合疫苗-TLR3复合物的得分分别为-299 kcal/mol、-361 kcal/mol、-258 kcal/mol和-312 kcal/mol。分子动力学模拟和解离常数分析证实了这些相互作用的强度,结合自由能范围为-57.75 kcal/mol至-101.35 kcal/mol。密码子适应指数(CAI)值为0.96,GC含量约为69%,支持疫苗构建体的高表达潜力。免疫模拟显示出强大的免疫反应,其特征为IgG、IgM、细胞因子和白细胞介素升高,以及有效的抗原清除。
与TLR3的强分子相互作用和模拟的免疫反应表明,设计的疫苗可以激活先天免疫和适应性免疫。高CAI和GC值支持它们在[具体宿主]中的表达可行性,增强了生产前景。
本研究为开发安全有效的EV-D68疫苗提供了坚实基础,展示了计算疫苗设计的潜力。